Oral anticoagulation therapy with either vitamin K antagonist (VKA) or non-oral anticoagulants (NOAC) is the mainstay of the stroke prevention therapy among<unk>  with<unk><unk>  (AF). Antithrombotic therapy consisting of dual antiplatelet drugs is administered among<unk>  with acute coronary syndrome <unk>  with or without percutaneous coronary<unk>  <unk>  or those undergoing<unk> lar<unk> . A challenge in the treatment decision exists among<unk><unk><unk>  who present with acute coronary syndrome <unk>  with or without percutaneous coronary<unk>  <unk>  or those those require<unk> lar<unk> s. In this category of<unk> , the treatment regimen should be chosen carefully in order to achieve a balance between ensuring prevention of stroke and ischemic events and not increasing the risk of bleeding. In order to choose a treatment regimen for<unk><unk><unk>  who present with acute coronary syndrome <unk>  with or without percutaneous coronary<unk>  <unk>  or those those require<unk> lar<unk> s, the risk of stroke and the risk of bleeding must be assessed using CHA2DS2-VASc score and HAS-BLED score, respectively.
Atrial fibrillation medical therapy in patients presenting with ACS and/or PCI or valve intervention
Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention
Chronic stable angina treatment calcium channel blockers
Chronic stable angina treatment potassium channel openers
Chronic stable angina treatment angiotensin converting enzyme inhibitors 
Chronic stable angina treatment beta blockers
Supraventricular tachycardia AHA recommendations for Management of IST
Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for warfarin therapy